Visby Medical Secures Funding for Innovative Health Solutions
Visby Medical™, a leading innovator in rapid, at-home polymerase chain reaction (PCR) diagnostics, has successfully completed a financing round, raising up to $65 million. This significant investment, primarily led by Catalio Capital Management, marks a pivotal moment for the company as it accelerates its mission to transform healthcare delivery.
Funding and Strategic Partnerships
Catalio Capital Management, well-known for their focus on innovative healthcare investments, spearheaded this funding initiative. The round gained support from notable existing investors such as ND Capital, Cedars Sinai Medical Center, Blue Water Life Science Advisors, and Pitango Ventures. This influx of capital is aimed directly at expediting the availability of Visby Medical's recently FDA-authorized at-home Women's Sexual Health Test.
New Board Members Bringing Expertise
As part of this financing, two impactful industry leaders, Isaac Ro and Chuck Alpuche, are joining Visby Medical's board. Isaac Ro from Catalio will enhance the company's operational capabilities and market reach as a board observer. Chuck Alpuche, recognized for his extensive background in operational leadership and manufacturing, will also contribute as an independent director, bringing invaluable insights to the team.
Transforming At-Home Healthcare Access
Adam de la Zerda, PhD, the founder and CEO of Visby Medical, expressed enthusiasm about this partnership. "We are thrilled to collaborate with Catalio Capital Management, a significant force in the industry. This funding will enable us to deliver our innovative at-home STI test, allowing people to obtain accurate health information conveniently and affordably."
A Game-Changer in Diagnostics
Visby Medical's at-home Women’s Sexual Health Test stands out as the first disposable PCR diagnostic tool yielding results within just 30 minutes. The test is fully integrated with a smartphone app, making it accessible and user-friendly. Users who receive positive results can effortlessly connect to telemedicine providers, facilitating immediate consultation and treatment.
About Catalio Capital Management
Catalio Capital Management, headquartered in New York, is dedicated to innovative healthcare investments throughout the various stages of the investment cycle. Their unique collaborations with top-tier scientists emphasize their commitment to groundbreaking healthcare solutions. With offices in New York, London, and Washington, D.C., Catalio continues to pave the way for advancements in healthcare.
About Visby Medical™
Founded in 2012, Visby Medical is changing the landscape of infectious disease diagnosis. Their cutting-edge technology enables accurate testing for infections whenever needed. The company's revolutionary instrument-free, single-use PCR tests deliver lab-quality results in under 30 minutes, significantly benefiting both physicians and patients alike. Currently, Visby Medical provides FDA-cleared tests for sexually transmitted infections and respiratory infections, continuously expanding their platform to include more at-home and point-of-care tests.
Frequently Asked Questions
What recent funding has Visby Medical received?
Visby Medical has raised up to $65 million in its latest financing round, primarily led by Catalio Capital Management.
What new product is Visby Medical launching?
The company is launching an at-home Women's Sexual Health Test that produces results in 30 minutes.
How does the at-home STI test work?
The test is a single-use disposable PCR diagnostic connected to a smartphone, enabling immediate access to healthcare services.
Who are the new board members for Visby Medical?
Isaac Ro from Catalio Capital and Chuck Alpuche have joined the Visby Medical board, bringing extensive industry experience.
What is the mission of Visby Medical?
Visby Medical aims to empower consumers with reliable health information through convenient at-home diagnostics that match traditional testing accuracy.
